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Introduction
• Long ago, in Block 6…

Introduction
• Diagnosis: Erythrodermic Psoriasis (secondary to oral
corticosteroids for plaque psoriasis)

Introduction
• For decades, dermatology teachings have cautioned against
the use of orally administered glucocorticoids (OAG) in the
treatment of psoriasis
• This is due to classically feared outcomes of generalized
pustular psoriasis (GPP) and erythrodermic psoriasis (EP)
• However, evidence shows that oral glucocorticoids are used
at high rates in the U.S. and Europe, often by dermatologists

Introduction
• Despite widespread use, there is scant data on treatment
outcomes
• Only one recent study (Gregoire 2020) has examined this
and found that rates of severe psoriasis flares may be low,
• The authors reported 1 case of erythroderma and no
pustular psoriasis among 1,970 patients treated with steroids
for psoriasis

Introduction
• We see an urgency to examine the relationship between
oral glucocorticoid usage and the development of GPP and
EP
• Demonstration of the safety of oral glucocorticoid use in
plaque psoriasis could revise existing standards of care

Objectives
& Hypothesis
• Research Question
– What is the prevalence of orally administered
glucocorticoid use in the management of plaque
psoriasis by U.S. dermatologists and the incidence of GPP
and EP in this context?

• Hypothesis
– The use of orally administered glucocorticoids is not
infrequent among US dermatologists and rarely
complicated by GPP or EP

Approach & Results
• Study design

– Online survey

• Population / study sample

– 143 US community and university-based dermatologists

• Outcome (dependent variable(s))

– Prevalence of oral glucocorticoids in the management of Plaque
Psoriasis
– Incidence of of GPP and EP in the context of oral glucocorticoid
tapering

• Data source and collection

– Written, self-administered, anonymous, closed format questionnaire

• Rationale for Approach

– To our knowledge, there are no prospective studies on OAG usagerelated studies involving psoriasis and GPP/EP
– A survey is limited but allowed us to gather data from a wider
sample of providers

Approach & Results
• Analysis
– Descriptive

• Findings
– 50 out of 143 U.S. community and university-based dermatologists
completed the survey
– Most dermatologists surveyed have been in clinical practice greater
than 10 years and see 6-10 patients with psoriasis per week

Approach & Results
• Findings
– 9 out of 50 (18%) of respondents reported occasionally prescribing
OAG to patients with psoriasis, typically 1-5% of the time
– Dermatologists who prescribe OAG tended to be younger than
those who did not, with two-thirds in clinical practice for <10 years
PRESCRIBE ORAL GLUCOCORTICOID
FOR PSORIASIS
Occasionally
18%

Never
82%

Approach & Results
• Findings
– 8 out of 50 (16%) of respondents had experienced one or more
patients developing GPP/EP in the presence of OAG treatment
– All respondents (98%) were aware of the risk in patients with
psoriasis of developing GPP and EP in the context of OAG treatment
– GPP was most commonly seen, while EP was not noted
– Critical illness was infrequent; no deaths were reported
ENCOUNTERED GPP/EP DURING ORAL
GLUCOCORTICOID USE FOR PSORIASIS
Yes
16%
No
84%

Conclusions
• OAG for the management of psoriasis is not uncommon
among U.S. dermatologists, despite nearly universal
awareness of its risks
• A substantial percentage of respondents have seen at least 1
case of OAG-related GPP/EP
• However, in view of the high prevalence of psoriasis in the
U.S., the actual rate may be low
• If OAG is to be accepted as as a safe psoriasis therapeutic,
prospective studies are needed to fully characterize their
risk/benefit profile

Future Directions
• We are submitting a brief report to JAMA Derm
• We plan to conduct a similar study in a European
population
• This is the first step towards further prospective studies on
OAG use in psoriasis and outcomes of GPP and EP
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